Deep genome sequencing reveals thatcancer-causing or cancer-sustaining molecular mechanisms can be shared across tumors of distinct origins. The Therapies for Rare Cancers (TRaC) program will develop drugs for rare cancers that share aberrations in DNA repair pathways. It integrates proteomics, genomics, structural and computational biology to identify and exploit regulators of repair pathway choice. Our goal is to develop compounds that force cancer cells into faulty repair pathways that kill them, or sensitize them to traditional therapies.

The Riddell Centre at the University of Calgary develops innovative immunotherapies for cancer patients with high unmet needs. This is achieved within a fully integrated bench-to-bedside research ecosystem that couples cutting-edge discovery and innovation science with rapid translation, into early phase clinical trials. Our team supports this work through antigen discovery, binder development and fundamental research into immune modulation and cell-cell communication.